KRYS · ISSUER CIK 1711279
Krystal Biotech, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Krystal Biotech, Inc. insiders reported $0.00 of open-market purchases and $26.2M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$26.2MInsider selling
−$26.2MNet open-market
Sep 4, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 202619:15 | Sep 4, 2026 | KRYS | President, R&D, Director, 10% Owner | S · Sell10b5-1 | $359.32 | −25,000 | 1,302,145 | -2% | −$9.0M | ||
| Sep 4, 202619:14 | Sep 4, 2026 | KRYS | President and CEO, Director, 10% Owner | S · Sell10b5-1 | $359.32 | −25,000 | 1,347,543 | -2% | −$9.0M | ||
| Aug 14, 202618:22 | Aug 14, 2026 | KRYS | Director | S · Sell | $329.12 | −25,000 | 50,000 | -33% | −$8.2M | ||
| Aug 14, 202618:22 | Aug 14, 2026 | KRYS | Director | G · Gift | — | −3,691 | 75,000 | -5% | — |